moneyheap
BNTX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is BioNTech SE American Depositary Share (BNTX) stock moving?
BNTX closed at $87.21 on Nov 10, below the $90.70 close on Nov 4 and within a 30-day range of $84.89 to $92.73. The stock fell 5.3% on Nov 5 to $85.86 on 1.19M shares, the session after the analyst target cuts, and has since traded around $86 to $88. Volume on Nov 10 was 694K shares, below the roughly 975K 30-day average, so the $205M Priority Review Voucher deal drew a muted reaction. Fundamentals are mixed: Q3 revenue was €1,289.2M, down about 15% year on year, and nine-month revenue of €1,512.9M was down about 23%. Nine-month net loss was €1,168.2M, although Q3 showed a €184.5M net profit against a loss a year earlier. R&D spending rose to €748.1M in Q3 from €564.8M. Full-year revenue guidance was narrowed to €1.7B-€1.9B, with the low end raised. The company held €16.2B in cash and securities and repurchased 5.04M ADSs for $463.3M at an average of $91.98 through Sep 30. Analysts kept Buy or Overweight ratings but cut targets to $106-$125, implying roughly 21%-43% upside from the current price. Risks include modest benefit and higher interstitial lung disease rates in the Phase 3 DYNASTY-Breast02 trial, the reported workplace culture allegations, and rising costs. From Jan 1, 2027, Roche takes over future R&D costs of its mRNA program from BioNTech, which is eligible for royalties.
News behind the analysis
- BioNTech To Acquire FDA Priority Review Voucher From Scholar Rock For $205M In CashBioNTech agreed to buy a US FDA Priority Review Voucher from Scholar Rock for $205M in cash. The voucher is meant to speed regulatory review of a future drug application.
- BioNTech to Acquire US FDA Priority Review Voucherfiscal.ai reported the same voucher acquisition, which is intended to expedite review of a future drug application.
- HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $110HC Wainwright kept its Buy rating and cut its price target to $110.
- UBS Maintains Buy on BioNTech, Lowers Price Target to $125UBS kept its Buy rating and lowered its price target to $125 from $135.
- Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $106Morgan Stanley kept its Overweight rating and trimmed its price target to $106.
- Wells Fargo Maintains Overweight on BioNTech, Lowers Price Target to $125Wells Fargo kept its Overweight rating and lowered its price target to $125.
- Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $110Evercore ISI kept its Outperform rating and lowered its price target to $110.
- Reports of workplace culture concerns and sexism allegations at BioNTechReports cite internal workplace culture concerns, including sexism allegations and complaints from the works council about the work environment.
- BioNTech Reports Third Quarter 2026 Financial Results and Updates Full-Year Revenue GuidanceQ3 revenue was €1,289.2M, down from €1,518.9M a year earlier, and Q3 net profit was €184.5M versus a loss. Full-year 2026 revenue guidance was narrowed to €1.7B-€1.9B.
- BioNTech Raises Low End Of FY26 Revenue Guidance; Now Sees €1.7B-€1.9B, From €1.6B-€1.9BThe low end of full-year 2026 revenue guidance was raised to €1.7B from €1.6B, with the high end unchanged at €1.9B.
About BioNTech SE American Depositary Share
BioNTech is a German biotech company based in Mainz that became widely known for developing the Pfizer-partnered COVID-19 mRNA vaccine (Comirnaty). It is now moving its focus toward cancer drugs, with a late-stage pipeline of immunotherapies, antibody-drug conjugates (ADCs) and mRNA treatments, and it aims to sell several products by 2030. Its US shares trade as ADRs on Nasdaq.
How it makes money
Almost all of its revenue still comes from its share of COVID-19 vaccine sales, which it splits with Pfizer, and these sales have been shrinking. Its 2026 revenue guidance is about €1.7–1.9 billion, and it expects to spend about €2–2.3 billion on research and development, so it currently loses money. It covers those costs with a large cash reserve of about €16 billion, as well as payments and cost-sharing from partners such as Bristol Myers Squibb on its pumitamig program.
What usually moves BNTX
- Clinical trial results for its cancer drugs, such as pumitamig and gotistobart
- Demand for COVID-19 vaccines and seasonal vaccination uptake
- Partnership deals and acquisitions
- Leadership change as the co-founders leave to start a new mRNA company
- Euro-to-dollar exchange rate